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A b s t r a c t  
Gastric emptying is a complex process and one of the most important obstacles in the better 
absorption and enhances bioavailability of oral drug delivery system. In recent years various 
scientific and technological advancements have been made in the research and development of oral 
drug delivery systems to overcoming physiological adversities, such as short gastric residence times 
(GRT) and unpredictable gastric emptying time (GET). In order to avoid such adversities, efforts 
have been made to increase the retention time of the drug-delivery systems for more than 12 hour 
via floating drug delivery system. Floating delivery systems or hydro dynamically controlled systems 
are low density systems that have sufficient buoyancy to float over the gastric content and remain 
buoyant in the stomach. The recent development of these systems includes their physiological and 
formulation variables affecting the gastric retention and to design the single and multiple-unit floating 
systems and their formulation, evaluation aspects are covered in detail. This article aims at 
reviewing the numerous techniques that has been designed till date for optimizing floating drug 
delivery system (FDDS), and also summarize the evaluation of FDDS of tablet dosage forms. 
Keywords: Gastro retentive systems, effervescent systems, non effervescent systems, gastric 
residence time, floating drug delivery systems, buoyancy. 
 
 
Introduction 
The focus of pharmaceutical research is steadily shifted from the 
development of new chemical entities to the development of novel 
drug delivery system of existing drug molecule to maximize their 
effectiveness in terms of therapeutic action, reducing frequency of 
dosing and wastage of drugs, patient compliance and reduced 
adverse effects [1]. To minimize drug degradation and loss, to 
prevent harmful side-effects and to increase drug bioavailability 
and the fraction of the drug accumulated in the required zone, 
various drug delivery and drug targeting systems are currently 
under development.  
Oral drug delivery is the most desirable and preferred method of 
drug delivery for achieving both systemic and local therapeutic 
effects. For many drugs, conventional oral formulations provide 
clinically effective therapy while maintaining the required balance 
of pharmacokinetic and pharmacodynamic profiles with an 
acceptable level of safety to the patient. The real challenge in the 
development of a controlled drug delivery system is not just to 
sustain the drug release but also to prolong the presence of the  
 
 
dosage form in the stomach or the upper small intestine until all 
the drug is completely released in the desired period of time [14, 
28] 
The gastro intestinal tract (GIT) is the major route of drug delivery 
to the systemic circulation. The normal GE t½ is 46.5 ± 5.5 
minutes [12, 36, 49, 60]. Oral controlled release dosage forms are 
not suitable for a variety of important drugs, characterized by a 
narrow absorption window in the upper part of the GIT. This is due 
to the relatively less transit time of the dosage form in these 
anatomical segments. Thus after only a short period of less than 6 
h, the controlled release formulation has already left the upper 
GIT and the drug is released in short, non absorbing distal 
segment of the GIT. This results in a short absorption phase, 
which is then accompanied by lesser bioavailability. These types 
of problem can be overcome by FDDS.  
After oral administration, such a delivery would be retained in the 
stomach and release the drug in a controlled manner so that the 
drug could be supplied continuously to its absorption sites. Hence, 
an advantageous drug delivery system to control and prolong the 
gastric emptying time and to deliver drugs in higher 
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concentrations to the absorption site necessitates a specialized 
delivery system. A significant approach in this regard can be 
achieved by floating drug delivery systems [29, 63]. The controlled 
gastric retention of solid dosage forms may be achieved by the 
mechanisms of mucoadhesion [37, 50], flotation [13], 
sedimentation [11, 53], expansion [40, 66], modified shape 
systems [16, 35], or by the simultaneous administration of 
pharmacological agents [22, 23] that delay gastric emptying. 
 
Definition of floating drug delivery systems     
                                                                                                                                                                          
The concept of floating drug delivery system (FDDS), was 
described in literature as early as 1968 .Floating dosage forms 
are oral dosage forms of tablets [39], capsules, or micro beads 
and contain hydrocolloids that allow floating by swelling thereby 
prolong the residence time of dosage form within gastro intestinal 
tract (GIT) [55]. 
 Floating systems are low-density systems that have sufficient 
buoyancy to float over the gastric contents and remain in the 
stomach for a prolonged period. While the system floats over the 
gastric contents, the drug is released slowly at the desired rate, 
which results in increased gastro-retention time and reduces 
fluctuation in plasma drug concentration. 
Techniques of gastric retention 
Various techniques were used to encourage gastric retention of 
an oral dosage form. Floating systems have low bulk density [52], 
so that they can float on the gastric juice in the stomach. The 
problem arises when the stomach is completely emptied of gastric 
fluid in such a situation; there is nothing to float on. Different 
techniques used for gastric retention [27] are mentioned below, 
1.Hydro dynamically balanced system (HBS) 
High-density system 
Swelling system 
2. Expansion or Modified shape system 
Bioadhesive or Mucoadhesive system 
Hydrodynamically balanced systems  
While the system is floating on the gastric contents the drug is 
slowly released from the low density pellets or floating drug 
delivery systems are also called as hydro dynamically balanced 
systems (HBS). FDDS or HBS have a bulk density lower than 
gastric fluid, that is, bulk density of less than one. HBS remains 
buoyant in the stomach without affecting the gastric emptying rate 
for a prolonged period of time and the drug is released slowly at a 
desired rate from the system. After the release of the drug, the 
residual system is emptied from the stomach [10]. The 
incorporated buoyant materials enable the device to float [29, 45]  
High-density system 
Sedimentation has been employed as a retention mechanism for 
pellets that are small enough to be retained in the folds of the 
stomach body near the pyloric region, which is the part of the 
organ with the lowest position in an upright posture. Dense pellets 
(approximately 3g/cm3) trapped in fold also tend to withstand the 
peristaltic movements of the stomach wall. With pellets, the GI 
transit time can be extended from an average of 5.8 – 25 hours, 
depending more on density than on diameter of the pellets. 
Commonly used excipients [51] are barium sulphate, zinc oxide, 
titanium dioxide and iron powder, etc. These materials increase 
density by up to 1.5-2.4g/cm3. This formulation of high-density 
pellet is based on assumption that heavy pellets might remain 
longer in the stomach, since they are position in the lower part of 
the antrum [4, 62, 64]. A number of other methods like use of 
passage-delaying agents [16, 21, 38, 47] and modified shape 
systems [6, 35] have also been used for gastroretention purpose. 
Swelling and expansion systems  
These dosage forms are larger than the pyloric opening and so 
are retained in the stomach. There are some drawbacks 
associated with this approach; permanent retention of rigid large-
sized single-unit forms can cause bowel obstruction, intestinal 
adhesion and gastroplasty. It can be referred as Plug-Type 
systems Polymers in the systems swell at a very faster rate and 
with higher degree to form a swollen matrix of which size is 
greater than that of the pylorus [18, 56]. The rate and extent of 
swelling are important parameters. The rate of swelling and rate 
of erosion are also important.  
Modified shape systems: 
Modified shape systems are non-disintegrating geometric shapes 
molded from silastic elastomer or exuded from polyethylene 
blends and extended the GIT depending on the size, shape and 
flexural modulus of the drug delivery device. 
Bioadhesive or Mucoadhesive systems: 
Bioadhesive system enabling the localized retention of the system 
in the stomach. The proposed mechanism of bioadhesive is the 
formation of hydrogen and electrostatic bonding at the mucus 
polymer boundary [45]. 
Approaches to FDDS  
Several techniques are reported in the literature to increase the 
gastric retention of drugs [7, 44, 57]  
Single-unit dosage forms 
A. Low density approach of single unit dosage 
forms 
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In low density approach [13] the globular shells apparently having 
low density than that of gastric fluid can be used as a carrier for 
drug for its controlled release. A buoyant dosage form can also be 
obtained by using a fluid-filled system that floats in the stomach. 
In coated shells popcorn, pop rice and polystyrol have been 
exploited as drug carriers. Sugar polymeric materials such as 
methacrylic polymer and cellulose acetate phthalate have been 
used to undercoat these shells. These are further coated with a 
drug polymer mixture. The polymer of choice can be either ethyl 
cellulose or hydroxypropylcellulose depending upon the type of 
release desired. Finally, the product floats on the gastric fluid 
while releasing the drug gradually over a prolonged duration. 
B. Hydro dynamically balanced systems (HBS) 
[9] 
HBS system containing a homogenous mixture of drug and a 
hydrocolloid in a capsule which upon contact with gastric fluid 
acquired and maintained a bulk density less than 1 , thereby  
being buoyant on the gastric contents of stomach until all the drug 
was released. 
The HBS is a novel dosage form which when in contact with 
gastric fluid and after dissolution of outer exposed surface of the 
dosage form, forms a hydrated gel layer and maintained bulk 
density less than 1g/cm3. Thus this system remains buoyant in 
the gastric fluid inside the stomach for 6hrs. The increase in 
retention time of HBS may also be due to effects the adhesion to 
the gastric mucosa, rather than the effect of floating. 
Conventional dosage form disintegrate within 60minutes and are 
emptied totally from the stomach shortly afterwards. This dosage 
form releases the drug through the hydrated layer by diffusion 
principle. This system is valuable for drugs which are soluble at 
lower pH and have an absorption window in the upper GIT. By 
varying the composition of the excipient between 25% to 75%w/w 
of one or more gel forming hydrocolloids such as 
hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropyl 
methylcellulose and sodium carboxy methylcellulose, the granules 
are prepared and compressed into tablets or encapsulated into 
capsules ,which results in the desired release rate of drug. This 
hydrated gel controls the rate of solvent penetration into the 
device and the rate of drug release from the device. 
Floating drug delivery device with self-activated mechanism for 
retaining the device in the stomach, which releases the drug 
under controlled osmotic pressure. The device was found to 
consist of two chambers, one for the drug reservoir and the other 
osmogen. In the stomach the gastric fluid dissolves the osmogen, 
which creates pressure on the drug reservoir compartment; this 
pressure tends to reduce the total volume of the drug reservoir 
compartment thereby leading to the continuous release of the 
drug material from the device. 
Next approach is the HBS capsule for the sustained release of the 
drug in the stomach by incorporation of liquid such as ether in an 
inflatable chamber. These are designed to prolong the stay of the 
dosage form in the gastrointestinal tract as an aid in enhancing 
the absorption. Such systems are best suited for drugs having 
better solubility in acidic environment and also for the drugs 
having specific site of absorption in the upper part of small 
intestine. To remain in the stomach for a prolonged period of time 
the dosage form must have a bulk density of less than 1. It should 
stay in the stomach, maintain its structural integrity and release 
drug constantly from the dosage form. However, there may be 
rare exceptions, where the presence or absence of food the 
stomach has no effect on the absorption of a drug from HBS type 
dosage forms. The success of HBS capsule as a better system is 
best exemplified with chlorodiazepoxide hydrochloride 
comparable blood level time profile as of three 10-mg commercial 
capsules. The drug is a classical example of a solubility problem 
where in it exhibits a 4000-fold difference in solubility going from 
pH 3 to 6 (the solubility of chlorodiazepoxide hydrochloride is 
150mg/ml and is ~0.1mg/ml at neutral pH) 
Multiple-unit dosage form 
Single unit formulations are associated with problems such as 
sticking together or being obstructed in gastrointestinal tract, 
which may have a potential danger of producing irritation. Multiple 
unit systems avoid the ‘all-or-none’ gastric emptying nature of 
single unit systems. It reduces the intersubject variability in 
absorption and the probability for dose dumping is lowers [33]. In 
carbon dioxide-generating multiple-unit oral formulations several 
devices with features that extend, unfold, or are inflated by carbon 
dioxide generated in the devices after administration have been 
described in the recent patent literature.   
Classification of floating drug delivery systems 
Based on the mechanism of buoyancy two distinctly different 
technologies, have been utilized in the development of FDDS: 
1. Effervescent system 
1.1 Volatile liquid containing systems 
1.2 Gas generating systems 
2. Non-effervescent system 
2.1 Colloidal gel barrier systems 
2.2 Microporous compartment system 
2.3  Alginate beads 
2.4 Hollow microspheres / Microballons 
Effervescent system 
Volatile liquid containing systems 
The GRT of a drug delivery system can be sustained by 
incorporating an inflatable chamber, which contains a liquid e.g. 
ether, cyclopentane, that gasifies at body temperature to cause 
the inflatation of the chamber in the stomach. 
The device may also consist of a bioerodible plug made up of poly 
vinyl alcohol, Polyethylene, etc. that gradually dissolves causing 
the inflatable chamber to release the gas and collapse after a 
predetermined time to permit the spontaneous ejection of the 
inflatable system from the stomach [31]. 
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Intragastric floating gastrointestinal drug 
delivery system 
This system can be made to float in the stomach, because of 
floating chamber, which may be a vacuum of filled with air or a 
harmless gas, while drug reservoir is encapsulated inside a micro 
porous compartment.  
Inflatable gastrointestinal delivery system 
In these systems an inflatable chamber is incorporated, which 
contains liquid ether that gasifies at body temperature to cause 
the chamber to inflatable in the stomach. These systems are 
fabricated by loading the chamber with the drug reservoir, which 
can be a drug impregnated polymeric matrix, than encapsulated in 
a gelatin capsule. After oral administration the capsule dissolves 
to release the drug reservoir together with the inflatable chamber. 
The inflatable chamber automatically inflates and retains the drug 
reservoir into the gastric fluid [31]. 
Intra gastric osmotically controlled drug 
delivery system 
It is comprised of an osmotic pressure controlled drug delivery 
device and an inflatable floating support in a biodegradable 
capsule. In the stomach, the capsule quickly disintegrates to 
release the intra gastric osmotically controlled drug delivery 
device. The inflatable support inside forms a deformable hollow 
polymeric bag that contains a liquid that gasifies at body 
temperature to inflate the bag [9]. 
The osmotic pressure controlled drug delivery device consists of 
two components, drug reservoir compartment and an osmotically 
active compartment. The drug reservoir compartment is enclosed 
by a pressure responsive collapsible bag, which is impermeable 
to vapour liquid and homo drug delivery orifice. The osmoticallly 
active compartment contains an osmotically active salt is 
enclosed within a semi permeable housing. In the stomach, the 
water in the gastrointestinal fluid is continuously absorbed through 
the semi permeable membrane into osmotically active 
compartment to dissolve the osmotically active salt. An osmotic 
pressure is then created which acts on the collapsible bag in turn 
forces the bag reservoir compartment to reduce its volume and 
activate the drug release through the delivery orifice. Gas 
generating system 
These buoyant delivery systems utilize effervescent reaction 
between carbonate or bicarbonate salts and citric or tartaric acid 
to liberate carbon dioxide. The liberated carbon dioxide gets 
entrapped in the hydrocolloid layer of the system. Thus the 
specific gravity decreases and the system begins to float [56, 62]. 
The common approach used for the preparation of these systems 
involves resin beads loaded with bicarbonate and coated with 
ethyl cellulose. The coating, which is insoluble but permeable, 
allows permeation of water. Thus carbon dioxide is released, 
causing the beads to float in the stomach .Other reported 
approaches and materials that have been reported are highly 
swellable hydrocolloids and light mineral oils, a mixture of sodium 
alginate and sodium bicarbonate, multiple unit floating pills that 
generate carbon dioxide when ingested, floating mini-capsules 
with a core of sodium bicarbonate, lactose and polyvinyl 
pyrrolidone coated with hydroxypropyl methylcellulose (HPMC), 
and floating 
systems based on ion exchange resin technology etc. [17]. These 
kinds of systems float completely within 10 minutes and remain 
floating over an extended period of 5-6 hrs [5, 59].   
Non-effervescent systems [31, 43, 65, 70]  
This type of system after swallowing swells unrestrained via. 
Imbibitions of gastric fluid to an extent that it prevents their exit 
from the stomach. These systems may be referred to as the “plug 
type system” since they have a tendency to remain lodged near 
the pyloric sphincter. One of the formulation methods of such 
dosage forms involves the mixing of drug with a gel, which swells 
in contact after oral administration and maintains a relative 
integrity of shape and a bulk density of less than 1. This is based 
on the mechanism of swelling of polymer or bio adhesion to 
mucosal layer in GIT. The most commonly used excipients are gel 
forming materials such as polycarbonate, poly acrylate, 
polystyrene etc. this hydrocolloid starts to hydrate by first forming 
a gel at the surface of the dosage form. The resultant gel structure 
then controls the rate of diffusion of solvent-in and drug-out of the 
dosage form. The various types of this system are as follows: 
Single layer floating tablets 
This can be formulated by intimate mixing of drug with gel forming 
hydrocolloid, which swells in contact with gastric fluid and 
maintain bulk density of less than 1. The air entrapped by the 
swollen polymer confers buoyancy to these dosage forms. 
Bilayer floating tablets 
A bilayer tablet contains 2 layers, one is immediate release layer 
which releases the initial dose from system while the other is 
sustained release layer which absorbs the gastric fluid and 
maintains a bulk density of less than 1 and thereby it remains 
buoyant in the stomach (Fassihi and Yang developed a zero-order 
controlled release) [69]. Multilayer tablet composed of at least 2 
barrier layers and one drug layer. All the layers are made of 
swellable, erodible polymers and the tablet was found to swell on 
contact with aqueous medium. As the tablet dissolved, the barrier 
layers eroded away to expose more of the drug. Gas evolving 
agent is added in either of the barrier layers, this caused the tablet 
to float and increased the retention of tablet in a patient’s 
stomach. 
Colloidal gel barrier systems 
This system was first developed by Sheth and Tossounian [58]. It 
contains drug with gel forming hydrocolloids meant to remain 
buoyant on stomach contents. This system incorporates a high 
level of one or more gel forming highly swellable cellulose type 
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hydrocolloids. On coming in contact with gastric fluid, the 
hydrocolloids in the system hydrate and form a colloidal gel 
barrier around the gel surface. The air trapped by the swollen 
polymer maintains a density less than unity and confers buoyancy 
to this dosage forms. 
Microporous Compartment System 
This technology is based on the encapsulation of drug reservoir 
inside a microporous compartment with aperture along its top and 
bottom wall [57]. The peripheral walls of the drug reservoir 
compartment are completely sealed to prevent any direct contact 
of the gastric mucosal surface with the un-dissolved drug. In 
stomach the floatation chamber containing entrapped air causes 
the delivery system to float over the gastric contents. Gastric fluid 
enters through the apertures, dissolves the drug, and carries the 
dissolved drug for continuous transport across the intestine for 
absorption. 
Alginate beads 
To develop Multi-unit floating dosage forms the freeze-dried 
calcium alginate has been used [67]. Spherical beads of 
approximately 2.5 mm in diameter can be prepared by the 
precipitation of calcium alginate via dropping sodium alginate 
solution into aqueous solution of calcium chloride. The beads are 
then separated snap and frozenin liquid nitrogen, and freeze dried 
at -40°C for 24 hours, leading to the formation of porous system, 
which can maintain a floating force over 12 hours. On the other 
hand, multiple-unit dosage forms appear to be better suited since 
they claimed to reduce the inter subject variability in - absorption 
and lower the probability of dose-dumping  
Hollow microspheres 
A novel emulsion solvent diffusion method was used to prepare 
hollow microspheres loaded with drug in their outer polymer shelf 
[33]. The ethanol: dichloromethane solution of the drug and 
enteric acrylic polymers is poured in to an agitated aqueous 
solution of PVA that was thermally controlled at 40°C.The gas 
phase generated in dispersed polymer droplet by evaporation of 
dichloromethane formed in internal cavity in microspheres of the 
polymer with drug. The microballons floated continuously over the 
surface of acidic dissolution media containing surfactant for 
greater than 12 hours. The drug released was high in pH 7.2 than 
in pH 6.8 [31]. Hollow microspheres (micro balloons), loaded with 
ibuprofen in their outer polymer shells were prepared by a novel 
emulsion-solvent diffusion method [46]. 
Ideal drug candidates for floating drug 
delivery 
v Drugs those are locally active in the stomach. Eg. 
Misoprostol, antacids etc. 
v Drugs which have narrow absorption window in the GIT. 
Eg. Furosemide, L-dopa, Para-amino benzoic acid, 
riboflavin.etc. 
v Drugs that exhibit low solubility at high pH values. Eg. 
Diazepam, Chlordiazepoxide, Verapamil hydrochloride. 
v Drugs that are unstable in the intestinal or colonic 
environment. E.g. captopril, ranitidine HCl, 
metronidazole. 
v Drugs that disturb normal colonic microbes. E.g. 
antibiotics against Helicobacter pylori. 
v Drugs having a specific site of absorption in the upper 
part of small intestine. 
v Drugs having a bulk density of less than 1 to remain in 
the stomach for a prolonged period of time. 
 
Factors affecting gastric retention 
Density  
GRT is a function of dosage form buoyancy that is dependent on 
the density. A buoyant dosage form having a density less than 
that of the gastric fluids floats, since it is away from the pyloric 
sphincter, the dosage unit is retained in the stomach for a 
prolonged period. A density of less than 1.004g/mL i.e. less than 
that of gastric contents has been reported. 
Size  
Dosage form units with a diameter of more than 7.5mm are 
reported to have an increased GRT compared with those with a 
diameter of 9.9mm.  
Shape of dosage form  
Tetrahedron and ring shaped devices with a flexural modulus of 
48 and 22.5 kilo pounds per square inch (KSI) are reported to 
have better GRT 90% to 100% retention at 24 hours compared 
with other shapes [19]. 
Single or multiple unit formulation 
Multiple unit formulations show a more predictable release profile 
and insignificant impairing of performance due to failure of units, 
allow co- administration of units with different release profiles or 
containing incompatible substances and permit a larger margin of 
safety against dosage form failure compared with single unit 
dosage forms. 
 Fed or unfed state 
Under fasting conditions, GI motility is characterized by periods of 
strong motor activity or the migrating myoelectric complex (MMC) 
that occurs every 1.5 to 2 hours. The MMC sweeps undigested 
material from the stomach. However, in the fed state, MMC is 
delayed and GRT is considerably longer [64]. 
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Nature of meal  
Feeding of indigestible polymers or fatty acid salts can change the 
motility pattern of the stomach to a fed state, thus decreasing the 
gastric emptying rate and prolonging drug release [68]. 
Caloric content  
GRT can be increased by 4 to 10 hours with a meal that is high 
in proteins and fats. 
Frequency of feed  
The GRT can increase by over 400 minutes, when successive 
meals are given compared with a single meal due to the low 
frequency of MMC [31] 
Gender  
Mean ambulatory GRT in males (3.4±0.6 hours) is less compared 
with their age and race matched female counterparts (4.6±1.2 
hours), regardless of the weight, height and body surface.  
Age  
Low gastric emptying time is observed in elderly than do in 
younger subjects.  Intrasubject and intersubject variations also are 
observed in gastric and intestinal transit time. Elderly people, 
especially those over 70 years have a significantly longer GRT 
[43].  
Posture  
GRT can vary between supine and upright ambulatory states of 
the patient. An upright position protects floating forms against 
postprandial emptying because the floating form remains above 
the gastric contents irrespective of its size [43].  
In supine subjects large dosage forms (both conventional and 
floating) experience prolonged retention. The gastric retention of 
floating forms appear to remain buoyant anywhere between the 
lesser and greater curvature of the stomach. On moving distally, 
these units may be swept away by the peristaltic movements that 
propel the gastric contents towards the pylorus, leading to 
significant reduction in GRT compared with upright subjects [7].  
Concomitant intake of drugs 
Drugs such as Metoclopramide, Cisapride, Codeine, Atropine and 
Propantheline may affect the performance of FDDS. The co-
administration of GI‐motility decreasing drugs can increase gastric 
emptying time [7].  
Methodology 
Direct compression technique 
Involves compressing tablets directly from powdered material 
without modifying the physical nature of the material itself. Direct 
compression vehicles or carriers must have good flow and 
compressible characters these properties are imparted by 
predisposing these vehicles to slugging, spray drying or 
crystallization. Most commonly used carriers are di calcium 
phosphate trihydrate, tri calcium phosphate etc. 
Melt granulation technique 
It is a process by which the pharmaceutical powders are 
agglomerated by using a melt able binder and no water or organic 
solvents are required for granulation. Because there is no drying 
step, the process is less time consuming and uses less energy. 
Granules were prepared in a lab scale high shear mixer, using a 
jacket temperature of 60 °c and an impeller speed of 20000 rpm. 
Melt solidification technique 
This process involves emulsification of the molten mass in the 
aqueous   phase followed by its solidification by chilling. The 
carriers used for this technique are lipids, waxes, polyethylene 
glycols. Drug is incorporated into these carriers to achieve 
controlled release. 
Wet granulation technique 
Wet granulation process involves the wet massing of powders, 
wet sizing or 
milling and drying. Wet granulation forms the granules by binding 
the powders together with an adhesive instead of compaction. 
The wet granulation technique employs a solution suspension or 
slurry containing a binder which is usually added to the powder 
mixture however the binder may be incorporated into the dry 
powder mix and the liquid may be added by itself. The method of 
introducing the binder depends on its solubility and on the 
components of the mixture since, in general, the mass should 
merely be moist rather than wet or pasty, and there is a limit to the 
amount of solvent that may be employed. Once the granulating 
liquid has been added mixing continues until a uniform dispersion 
is attained and all the binder has been activated. Then the wet 
mass is made to undergo wet screening by passing through a 
hammer mill or multi mill equipped with screens having large 
perforations. The milled wet mass is dried by either using tray 
drier or fluidized bed drier, after complete the drying lubrication 
materials is blended with dried granules. This lubricated granules 
is made to undergo compression. 
Effervescent technique:                                                                 
The floating chamber of the drug delivery system can be filled with 
inert gas [CO2] by the effervescent reaction between organic acid 
[citric acid] and bicarbonate salts. 
Spray drying techniques: 
Kamalakkannan et al. International Journal of Drug Delivery 3 (4) 558-570 [2011] 
 
PAGE | 564 | 
 
 
It involves dispersing the core material in a liquefied coating 
material and spraying the core-coating mixture in to the 
environment to effect solidification of coating. Solidification is 
accomplished by rapid evaporation of the solvent in which coating 
material is solubilised.  
Formulation of FDDS 
Following types of the ingredients can be incorporated in to HBS 
dosage form 
v Hydrocolloids 
v Inert fatty materials 
v Release rate accelerants 
v Release rate retardants 
v Buoyancy increasing agents 
v Miscellaneous 
Hydrocolloids 
Suitable hydrocolloids are synthetics, anionic or non ionic like 
hydrophilic gums, modified cellulose derivatives. E.g. Acacia, 
pectin, agar, alginates, gelatin, casein, bentonite, veegum, 
methylcellulose, hydroxypropylcellulose, hydroxyethylcellulose, 
and carboxymethylcellulose sodium can be used. The 
hydrocolloids must hydrate in acidic medium i.e. gastric fluid is 
having pH 1.2. 
Inert fatty materials  
Edible, pharmaceutical inert fatty material, having a specific 
gravity less than one can be added to the formulation to decrease 
the hydrophilic property of formulation and hence increases the 
buoyancy. E.g. Purified grades of beeswax, fatty acids, long chain 
alcohols, glycerides, and mineral oils can be used.  
 Release rate accelerants 
The release rate of the medicament from the formulation can be 
modified by including excipient like lactose and/or mannitol. These 
may be present from about 5-60% by weight. 
Release rate retardants 
Insoluble substances such as calcium phosphate, talc, 
magnesium Stearate decreased the solubility and hence retard 
the release of medicaments. 
Buoyancy increasing agents 
Materials like ethyl cellulose, which has bulk density less than 
one, can be used for enhancing the buoyancy of the formulation. 
It may be adapted up to 80 % by weight. 
Miscellaneous 
Pharmaceutically acceptable adjuvant like preservatives, 
stabilizers, and lubricants can be incorporates in the dosage 
forms as per the requirements. They do not adversely affect the 
hydrodynamic balance of the systems [48]. 
Advantages [2, 26] 
v The Principle of HBS may not limit to any particular 
medicament or class of medicament. 
v The HBS formulations are not restricted to 
medicaments, which are absorbed from stomach, since 
it has been found that these are equally efficacious with 
medicament, which absorbed from the intestine. 
v Acidic substances like aspirin cause irritation on the 
stomach wall when come in to contact with it. Hence 
HBS formulation may be useful for the administration of 
aspirin and other similar drugs. 
v The HBS are advantageous for drugs absorbed through 
the stomach. E.g. Ferrous salts, antacids. 
v The efficacy of the medicaments administered utilizing 
the sustained release principle of HBS formulation has 
been found to be independent on the site of particular 
medicaments. 
v The HBS are advantageous for drugs meant for local 
action in the stomach. E.g. Antacids. 
v Administration of prolongs release floating dosage 
forms, tablet or capsules, will results in dissolution of the 
drug in the gastric fluid. They dissolve in the gastric fluid 
would be available for absorption in the small intestine 
after emptying of the stomach contents. It is therefore 
expected that a drug will be fully absorbed from the 
floating dosage forms if it remains in the solution form 
even at the alkaline pH of the intestine. 
v When there is vigorous intestinal movement and a 
shorted transit time as might occur in certain type of 
diarrhea, poor absorption is expected. Under such 
circumstances it may be advantageous to keep the drug 
in floating condition in stomach to get a relatively better 
response 
Disadvantages of floating drug delivery system 
v Floating system is not feasible for those drugs that have 
solubility or stability problem in GI tract. 
v These systems require a high level of fluid in the 
stomach for drug delivery to float and work efficiently-
coat, water [42] 
v The drugs that are significantly absorbed throughout 
gastrointestinal tract, which undergo significant first 
pass metabolism, may not be desirable candidate. E.g. 
Nifedipine. 
v The ability of drug to remain in the stomach depends 
upon the subject being positioned upright. 
v The residence time in the stomach depends upon the 
digestive state. Hence, FDDS should be administered 
after the meal. 
v Not suitable for drugs that cause gastric lesions e.g. 
Non steroidalanti inflammatory drugs. Drugs that are 
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unstable in the strong acidic environment, these 
systems do not offer significant advantages over the 
conventional dosage forms for drugs, which are 
absorbed throughout the gastro intestinal tract [41]. 
v The mucus on the walls of the stomach is in the state of 
constant renewal, resulting in the unpredictable 
adherence. 
v Faster swelling properties are required and complete 
swelling of the system should be achieved well before 
the gastric emptying time. 
v The ability to float relies in the hydration state of dosage 
form. 
v In all the above, the most important and primary 
requirement for the success is the physical integrity of 
the system. 
Evaluation of FDDS 
Different studies reported in the literature indicate that 
pharmaceutical dosage forms exhibiting gastric residence in vitro 
floating behavior show prolonged gastric residence in vivo. 
However, it has to be pointed out that good in vitro floating 
behavior alone is not sufficient proof for efficient gastric retention 
in vivo. Various parameters that need to be evaluated in 
gastroretensive formulations include floating duration, dissolution 
profiles, specific gravity, content uniformity, hardness, and 
friability in case of solid dosage forms. In the case of 
multiparticulate drug delivery systems, differential scanning 
calorimetry (DSC), particle size analysis, flow properties, surface 
morphology, mechanical properties and X-ray diffraction studies 
are also performed. Obviously, only in vivo studies can provide 
definite proof that prolonged gastric residence is obtained. 
Evaluation of FDDS of tablet dosage forms as follows;  
Thickness, Uniformity of weight, Content 
uniformity, Hardness, Friability and Assay 
These are the tests can be performed as per the procedures 
mentioned in the official monographs.  
Floating lag time and total floating time 
determination 
The time between the introduction of the tablet into the medium 
 
 
 and its rise to upper one third of the dissolution vessel is termed 
as floating lag time and the time for which the dosage form floats 
is termed as the floating or flotation time. These tests are usually 
performed in simulated gastric fluid or 0.1 M hydrochloric acid 
maintained at 37 °C, by using USP dissolution apparatus 
containing 900 ml of 0.1 molar hydrochloric acid as the dissolution 
medium [3]. 
Weight gain and water uptake 
Weight gain or water uptake (WU) can be studied by considering 
the swelling behavior of Floating dosage form. The study is done 
by immersing the dosage form in simulated gastric fluid at 37 °C 
and determining the dimensional changes like tablet diameter and   
or thickness at regular 1 h time intervals until 24 h, the tablets 
were removed from beaker, and the excess surface liquid was 
removed carefully using the paper. The swollen tablets were then 
reweighed and WU is measured in the terms of percent weight 
gain, as given by equation WU = (Wt – Wo) X 100 / Wo in which 
Wt and Wo are the weights of the dosage form at time t and 
initially, respectively [20]. 
In vitro drug release study 
Dissolution tests are performed using the USP dissolution 
apparatus. The test for in vitro drug release studies are usually 
carried out in simulated gastric fluid or 0.1 N hydrochloric acid 
fluids maintained at 37 °C. Samples are withdrawn periodically 
from the dissolution medium with replacement and then analyzed 
for their percentage drug release after an appropriate dilution. 
Standard methods based on the US Pharmacopoeia or British 
Pharmacopoeia have been shown to be poor predictors of in vitro 
performance for floating dosage forms. 
Conclusion 
Gastro retentive floating drug delivery system have emerged as 
an efficient means of enhancing the bioavailability and controlled 
drug delivery of many drugs. The currently available polymer-
mediated non effervescent and effervescent FDDS, designed on 
the basis of delayed gastric emptying and buoyancy principles, 
appear to be an effective and rational approach to the modulation 
of controlled oral drug delivery. The research in this area is 
ongoing on the concept of design of novel polymers according to 
clinical and pharmaceutical need. 
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Figure 1:  
 
 
 
 
Figure 2: Intragastric floating drug delivery device 
 
 
 
 
 
Figure 3: Gastro inflatable drug delivery device 
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Figure 4: Intra gastric osmotic controlled drug delivery system 
 
 
 
 
 
 
Figure 5: 
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Figure 6: 
 
 
 
Ideal candidates for making FDDS with respective dosage forms [8, 15, 24, 25, 30, 
32, 34, 54, 61] 
 
S.No Dosage Forms Drugs 
1 Floating microspheres Aspirin, Griseofulvin, p-nitro aniline, Ibuprofen, 
Terfinadine and Tranilast 
2 Floating granules Diclofenac sodium, Indomethacin and Prednisolone 
3 Films Cinnarizine 
4 Floating Capsules Chlordiazepoxide hydrogen chloride, Diazepam, 
Furosemide, Misoprostol, L-Dopa, Benserazide, 
Ursodeoxycholic acid and Pepstatin 
5 Floating tablets and Pills Acetaminophen, Acetylsalicylic acid, Ampicillin, 
Amoxycillin trihydrate, Atenolol, Diltiazem, 
Fluorouracil, Isosorbide mononitrate, Para- 
aminobenzoic acid, Piretamide, Theophylline and 
Verapamil hydrochloride 
 
